Top

Published in:

01-12-2020 | Mastectomy | ASO Author Reflections

ASO Author Reflections: Lobular Carcinoma of the Breast: Why Does the Incidence Continue to Rise?

Authors: Lisa Findlay-Shirras, MBBS, MSc, Angel Arnaout, MD, MSc, FRCSC, FACS, MBA

Published in: Annals of Surgical Oncology | Special Issue 3/2020

Excerpt

Previous studies have shown a general increase in invasive lobular carcinoma (ILC) rates over the 1980s to 1990s, however this was during a time when the use of combined hormone replacement therapy (CHRT), a known risk factor for breast cancer, was increased.1‐3 Following the 2002 report from the Women’s Health Initiative trial that showed CHRT use was associated with a 26% increased risk of breast cancer after more than 5 years, CHRT use has decreased significantly.4 With the decline of CHRT use following this ground-breaking trial, has this shift in practice translated into a sustained decrease in incidence of ILC since then? …

Thomas M, Kelly ED, Abraham J, Kruse M. Invasive lobular breast cancer: a review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol. 2019;46(2):121–132. https://doi.org/10.1053/j.seminoncol.2019.03.002.CrossRefPubMed

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–1059. https://doi.org/10.1186/bcr486.CrossRef

Chen C, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287(6):734–741.CrossRef

Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288(3):321–333.CrossRef

Findlay-Shirras LJ, Lima I, Smith G, Clemons M, Arnaout A. Population trends in lobular carcinoma of the breast: the Ontario experience. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08895-8.CrossRefPubMed

Bland K, Copeland E, Klimberg VS, Gradishar WJ. The breast: comprehensive management of benign and malignant diseases. 5th ed. Philadelphia, PA: Elsevier; 2017.

Title: ASO Author Reflections: Lobular Carcinoma of the Breast: Why Does the Incidence Continue to Rise?
Authors: Lisa Findlay-Shirras, MBBS, MSc
Angel Arnaout, MD, MSc, FRCSC, FACS, MBA
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Mastectomy
Breast Cancer
Breast Cancer
Published in: Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-020-08984-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ASO Author Reflections: Lobular Carcinoma of the Breast: Why Does the Incidence Continue to Rise?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 3/2020

ASO Author Reflections: Individualized Mediastinal Lymph Node Dissection for Lung Cancer: Do Not Neglect Station 3A Lymph Node

ASO Author Reflections: Margin-Positive Pancreatic Ductal Adenocarcinoma During Pancreaticoduodenectomy: Additional Resection Does Not Improve Survival

ASO Author Reflections: MicroRNA-Based Nomogram for Prediction of Sentinel Lymph Node Metastasis in ER+/HER2− Breast Cancer in Hoping for a Possible Omission of Sentinel Lymph Node Biopsy

ASO Author Reflections: Omitting Radiotherapy for Ductal Carcinoma In Situ Patients with Lumpectomy: Now or in the Future?

ASO Author Reflections: The Special Theory as an Entrance to the General Theory of Hepatoma Surgery

Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence